Alternative Health

Pharmaceutical Industry
Funding World-Wide Effort
to Restrict Access to Vitamins and Supplements

By Josef Hasslberger, Ph.D.

See our full line of Nutritional supplements

Recent legislative proposals on at least three continents have centered around the perceived need to ensure the safety of natural health products, such as supplements containing vitamins and minerals. Canada has proposed drug-style regulations for supplements. In the US, a proposal termed S 722 seeks to increase the FDA's powers to remove supplements from circulation. Australia recalled 1600 diverse health products in an unprecedented prelude to - what else - tighter regulations. Harmonization across the Tasman seeks to impose the already restrictive Australian rules on New Zealand. Here in Europe, a Directive on Food Supplements was approved, which many fear will remove thousands of hitherto safe products from the market in the name of 'consumer protection'. The transformation of this directive into national law is being challenged in a London Court by a coalition of groups and individuals made up of practitioners, consumers and a few manufacturers. The European Court of Justice will have to deal with the matter. As if that was not enough, Codex Alimentarius, an international standard-setting body for foods under the auspices of the World Health Organization is considering restrictions on Vitamins in international trade.

The one common line of justification for all this legislative fervour is: 'Consumer protection'. Hogwash, one might be tempted to say, when considering what New Zealand researcher Ron Law has found and described in a number of graphics: Vitamins and food supplements in general are by far the safest product category around. According to the government's own statistical data as published in prestigious medical journals and on government websites, supplements are far safer than even plain ordinary food.

On the other side, pharmaceutical medicines, correctly registered, approved and properly prescribed, are causing hundreds of thousands of deaths every year and have become a leading cause of death and injury.

So clearly, the consumer protection argument does not wash. Why protect anyone from something that is not dangerous while exposing them to government mandated medical peril?

Certainly there are pharmaceutical lobby interests that would be overjoyed at seeing severe restrictions for those pesky health foods that keep spoiling the bottom line. Business is business, to be sure. It is an essential trait of pharmaceutical business that it can only fluorish when illness is widespread. That is a hard fact, but one we tend to want to overlook - possibly we think we might be thought of as 'uncharitable' with our fellows in the medical and pharmaceutical field, if we did bring up the subject.

According to the definition of a medicinal product in the EU and elsewhere, prevention is, along with diagnosis and cure, a characteristic part of what we consider to be part of medicine. But in real life, prevention is incompatible with the business of cure. If I can prevent all diseases, no one will need a cure. So who is going to believe that - when given responsibility for both prevention and cure - I will seriously work on prevention? Only someone who cannot put two and two together. The money is in the cure - not in prevention.

What laughingly passes for 'prevention' in modern medicine, vaccination for one, lowering your cholesterol level for another - just to quote two egregious examples - is really an activity meant to drum up business for the 'cure' department. We know that vaccinations are not exactly strengthening the immune system, and that cholesterol lowering drugs, to some, are outright dangerous.

These facts are pretty obvious to anyone paying attention. So how could it be that pharma lobbies have such an easy time convincing legislators of the 'urgent need' to regulate supplements? What is the trick they are using?

Apart from slanted media reports and ordinary corruption, the pharma boys have hit upon a great idea: The 'reasonable' evaluation of vitamin safety by high power pharmaceutical experts and the consequent setting of 'Safe Upper Limits'. This is such a seemingly reasonable request that it has already been enshrined in the European Food Supplements Directive and is proposed in upcoming Codex regulations. What reasonable politician would not want to agree to 'scientifically sound' safety proposals for vitamins?

Unfortunately the 'safety evaluations' so far proposed are hopelessly slanted - so much so that the 'safe levels' arrived at in most cases are also 'no effect levels' meaning that the levels are useless for preventing anything but the most severe deficiency diseases, which incidentally have no longer been with us for decades.

Alan Gaby, M.D., has analyzed the question of 'upper safe limits' on the example of the UK 'Expert Group's report on Vitamins and Minerals'. His article is being published in the Journal of Orthomolecular Nutrition, in a Special Issue titled 'The Safety and Efficacy of Vitamins'. To get the full text with references, you will have to order the Journal, which also contains a number of other interesting articles.

"Safe Upper Limits" for nutritional supplements: one giant step backward

by Alan R. Gaby, M.D.

Editor's Note: For our USA readers this article refers to recent attempts to restrict access to vitamins and supplements in the UK and Europe. In the USA similar and related efforts are underway using false and biased science to support restrictions on essential nutrients.

In May, 2003, the "Expert Group on Vitamins and Minerals" (EVM), an advisory group originally commissioned in 1988 by the then Ministry of Agriculture Fisheries and Food, and subsequently reporting to the Food Standards Agency in England, published a report that set "Safe Upper Limits" (SULs) for the doses of most vitamin and mineral supplements. The establishment of SULs was based on a review of clinical and epidemiological evidence, as well as animal research and in vitro studies. For those nutrients for which the available evidence was judged insufficient to set a SUL, the EVM instead established "Guidance Levels", which were to be considered less reliable than SULs.

This writer's analysis of the EVM report reveals that the dose limits were set inappropriately low for many vitamins and minerals; well below doses which have been used by the public for decades with apparent safety. While the release of this 360-page document would be of little import, were it to be used solely as a manifesto for the pathologically risk-averse, preliminary indications are that it could be used very actively to support the arguments of those who are seeking to ban the over-the-counter sale of many currently available nutritional supplements. If the report is used that way, then the public health could be jeopardized.

On May 30, 2002, the European Union adopted Directive 2002/46/EC, which established a framework for setting maximum limits for vitamins and minerals in food supplements. The EVM report is seen by the UK government as the basis for its negotiating position in the process of setting these pan-European limits.

The apparent anti-nutritional-supplement, anti-self-care bias that permeated the process of setting safety limits is evident both in the way in which the SUL was defined and in the fact that the benefits of nutritional supplements were purposely ignored. The SUL was defined as the maximum dose of a particular nutrient "that potentially susceptible individuals could take daily on a life-long basis, without medical supervision in reasonable safety." In other words, it is the highest dose that is unlikely to cause anyone any harm, ever, under any circumstance. Furthermore, the EVM was specifically instructed not to consider the benefits of any of the nutrients, and not to engage in risk/benefit analysis.

There is little or no precedent in free societies for restricting access to products or activities to levels that are completely risk-free. Aspirin causes intestinal bleeding, water makes people drown, driving a car causes accidents, and free speech may offend the exquisitely offendable. Politicians and bureaucrats do not seek to ban aspirin or water or driving or free speech, because their benefits outweigh their risks. For vitamins and minerals, however, some authorities seem to believe that unique safety criteria are needed.

Moreover, the government's instructions to disregard the many documented benefits of nutritional supplements introduced a serious bias into the evaluation process. As the EVM acknowledged, determining safety limits involves an enormous degree of uncertainty and a fairly wide range of possible outcomes. The committee might have established higher safety limits than it did, had it been told to weigh benefits against risks. The government's instructions appeared to be an implicit directive to err on the side of excluding doses that are being used to prevent or treat disease. And that is what the EVM did, often by making questionable interpretations of the data, and doing so in what appears to have been an arbitrary and inconsistent manner.

Riboflavin Guidance Level

A typical example of the EVM's dubious approach to establishing safety limits is its evaluation of riboflavin. The committee acknowledged that no toxic effects have been reported in animals given an acute oral dose of 10,000 mg/kg of body weight, or after long-term ingestion of 25 mg/kg/day (equivalent to 1,750 mg/day for a 70-kg human). Moreover, in a study of 28 patients taking riboflavin for migraine prophylaxis, a dose of 400 mg/day for 3 months did not cause any adverse effects. Despite a complete absence of side effects at any dose in either humans or animals, the EVM set the Guidance Level for riboflavin at 40 mg/day. That level was established by dividing the 400 mg/day used in the migraine study by an "uncertainty factor" of 10, to allow for variability in the susceptibility of human beings to adverse effects.

A more appropriate conclusion regarding riboflavin would have been that no adverse effects have been observed at any dose, and that there is no basis at this time for establishing an upper limit. If the EVM's recommendation is used to limit the potency of riboflavin tablets to 40 mg, then migraine sufferers will have to take 10 pills per day, in order to prevent migraine recurrences.

Vitamin B6 Safe Upper Limit

Similar reasoning led to an SUL of 10 mg/day for vitamin B6, even though this vitamin has been used with apparent safety, usually in doses of 50 to 200 mg/day, to treat carpal tunnel syndrome, premenstrual syndrome, asthma, and other common problems. The SUL for vitamin B6 was derived from an animal study, in which a dose of 50 mg/kg of body weight/day (equivalent to 3,000 mg/day for a 60-kg person) resulted in neurotoxicity. The EVM reduced that dose progressively by invoking three separate "uncertainty factors:" 1) by a factor of 3, to extrapolate from the lowest-observed-adverse-effect-level (LOAEL) to a no-observed-adverse-effect-level (NOAEL); 2) by an additional factor of 10, to account for presumed inter-species differences; and 3) by a further factor of 10 to account for inter-individual variation in humans. Thus, the neurotoxic dose in animals was reduced by a factor of 300, to a level that excludes the widely used 50- and 100-mg tablets.

The decision to base the SUL for vitamin B6 on animal data (modified by a massive "uncertainty factor") was arbitrary, considering that toxicology data are available for humans. A sensory neuropathy has been reported in some individuals taking large doses of vitamin B6. Most people who suffered this adverse effect were taking 2,000 mg/day or more of pyridoxine, although some were taking only 500 mg/day. There is a single case report of a neuropathy occurring in a person taking 200 mg/day of pyridoxine, but the reliability of that case report is unclear. The individual in question was never examined, but was merely interviewed by telephone after responding to a local television report that publicized pyridoxine-induced neuropathy.

Because pyridoxine neurotoxicity has been known to the medical profession for 20 years, and because vitamin B6 is being taken by millions of people, it is reasonable to assume that neurotoxicity at doses below 200 mg/day would have been reported by now, if it does occur at those doses. The fact that no such reports have appeared strongly suggests that vitamin B6 does not damage the nervous system when taken at doses below 200 mg/day. As the EVM did with other nutrients for which a LOAEL is known for humans, it could have divided the vitamin B6 LOAEL (200 mg/day) by 3 to obtain an SUL of 66.7 mg/day. Had the committee been allowed to evaluate both the benefits and risks of vitamin B6, it probably would have established the SUL at that level, rather than the 10 mg/day it arrived at through serial decimation of the animal data.

Manganese Guidance Level

Chronic inhalation of high concentrations of airborne manganese, as might be encountered in mines or steel mills, has been reported to cause a neuropsychiatric syndrome that resembles Parkinson's disease. In contrast, manganese is considered one of the least toxic trace minerals when ingested orally, and reports of human toxicity from oral ingestion are "essentially nonexistent." The neurotoxicity that occurs in miners and industrial workers may result from a combination of high concentrations of manganese in the air and, possibly, direct entry of nasally inhaled manganese into the brain (bypassing the blood-brain barrier).

In establishing a Guidance Level for manganese, the EVM cited a study by Kondakis et al, in which people exposed to high concentrations of manganese in their drinking water (1.8-2.3 mg/L) had more signs and symptoms of subtle neurological dysfunction than did a control group whose drinking water contained less manganese. The committee acknowledged that another epidemiological study by Vieregge et al showed no adverse effects among individuals whose drinking water contained up to 2.1 mg/L of manganese. The EVM hypothesized that these studies may not really be contradictory, since the subjects in the Kondakis study were, on average, 10 years older than were those in the Vieregge study, and increasing age might theoretically render people more susceptible to manganese toxicity. Based on the results of these two studies, the EVM established a Guidance Level for supplemental manganese of 4 mg/day for the general population and 0.5 mg/day for elderly individuals.

There are serious problems with the EVM's analysis of the manganese research. First, the committee overlooked that fact that in the Kondakis study the people in the high-manganese group were older than were those in the control group (mean age, 67.6 vs. 65.6 years). Many of the neurological symptoms that were investigated in this study are nonspecific and presumably age related, including fatigue, muscle pain, irritability, insomnia, sleepiness, decreased libido, depression, slowness in rising from a chair, and memory disturbances. The fact that the older people had more symptoms than did the younger people is not surprising, and may have been totally unrelated to the manganese content of their drinking water.

Second, the EVM broke its own rules regarding the use of uncertainty factors, presumably to avoid being faced with an embarrassingly low Guidance Level for the general population. In setting the level at 4 mg/day, the committee stated: "No uncertainty factor is required as the NOAEL [obtained from the Vieregge study] is based on a large epidemiological study." As a point of information, the Nurses' Health Study was a large epidemiological study, enrolling more than 85,000 participants. The Beaver Dam Eye Study was a medium-sized epidemiological study, enrolling more than 3,000 participants. In contrast, in the Vieregge study, there were only 41 subjects in the high-manganese group, making it a very small epidemiological study. In its evaluation of the biotin, riboflavin, and pantothenic acid research, the EVM reduced the NOAEL by an uncertainty factor of 10, in part because only small numbers of subjects had been studied. Considering that more subjects were evaluated in the pantothenic acid research (n = 94) than in the Vieregge study (n = 41), it would seem appropriate also to use an uncertainty factor the for manganese data. Applying an uncertainty factor of 10 to the Vieregge study would have produced an absurdly low Guidance Level of 0.4 mg/day for supplemental manganese, which is well below the amount present in a typical diet (approximately 4 mg/day) and which can be obtained by drinking several sips of tea. Parenthetically, in a study of 47,351 male health professionals, drinking large amounts of tea (a major dietary source of manganese) was associated with a reduced risk of Parkinson's disease, not an increased risk. In changing its methodology to avoid reaching an indefensible conclusion, the EVM revealed the arbitrary and inconsistent nature of its evaluation process.

Niacin (nicotinic acid) Guidance Level

Large doses of niacin (such as 3,000 mg/day) can cause hepatotoxicity and other significant side effects. The EVM focused its evaluation, however, on the niacin-induced skin flush, which occurs at much lower doses. The niacin flush is a sensation of warmth on the skin, often associated with itching, burning, or irritation that occurs after the ingestion of niacin and disappears relatively quickly. It appears to be mediated in part by the release of prostaglandins. The niacin flush is not considered a toxic effect per se, and there is no evidence that it causes any harm. People who do not like the flush are free to not take niacin supplements or products that contain niacin. For those who are unaware that niacin causes a flush, an appropriate warning label on the bottle would provide adequate protection.

Granting, for the sake of argument, that the niacin flush is an adverse effect from which the public should be protected, the EVM's Guidance Level still is illogical. The committee noted that flushing is consistently observed at a dose 50 mg/day, which it established as the LOAEL. That dose was reduced by an uncertainty factor of 3, in order to extrapolate the LOAEL to a NOAEL. Thus, the Guidance Level was set at 17 mg/day, which approximates the RDA for the vitamin. The EVM also noted, however, that flushing has been reported at doses as low as 10 mg, so the true LOAEL is 10 mg/day. Applying the same uncertainty factor of 3 to the true LOAEL would have yielded a Guidance Level of a paltry 3.3 mg/day, which probably is not enough to prevent an anorexic person from developing pellagra. As with manganese, the EVM applied its methodology in an arbitrary and inconsistent manner, so as to avoid being faced with an embarrassing result.

Vitamin C Guidance Level

The EVM concluded that vitamin C does not cause significant adverse effects, although gastrointestinal (GI) side effects may occur with high doses. The committee therefore set a Guidance Level based on a NOAEL for GI side effects. It is true that taking too much vitamin C, just like eating too many apples, may cause abdominal pain or diarrhea. The dose at which vitamin C causes GI side effects varies widely from person to person, but can easily be determined by each individual. Moreover, these side effects can be eliminated by reducing the dose. Most people who take vitamin C supplements know how much they can tolerate; for those who do not, a simple warning on bottles of vitamin C would appear to provide the public all the protection it needs. Considering the many health benefits of vitamin C, attempting to dumb down the dose to a level that will prevent the last stomachache in Europe is not a worthwhile goal. However, as mentioned previously, the EVM was instructed to ignore the benefits of vitamin C.

Granting, for the sake of argument, that there is value in setting a Guidance Level for GI side effects, the EVM did a rather poor job of setting that level. The committee established the LOAEL at 3,000 mg/day, based on a study of a small number of normal volunteers. An uncertainty factor of 3 was used to extrapolate from the LOAEL to a NOAEL, resulting in a Guidance Level of 1,000 mg/day. However, anyone practicing nutritional medicine knows that some patients experience abdominal pain or diarrhea at vitamin C doses of 1,000 mg/day or less, and the EVM did acknowledge that GI side effects have been reported at doses of 1,000 mg. It is disingenuous to set a NOAEL and then to concede that effects do occur at the no-effect level. To be consistent with the methodology it used for other nutrients, the committee should have set the LOAEL at 1,000 mg/day, and reduced it by a factor of 3 to arrive at a NOAEL of 333 mg/day. The EVM was no doubt aware of the credibility problems it would have faced, had it suggested that half the world is currently overdosing on vitamin C. To resolve its dilemma, the committee used a scientifically unjustifiable route to arrive at a seemingly politically expedient outcome.

Conclusion

These and other examples from the report demonstrate that the EVM applied its methodology in an arbitrary and inconsistent manner, in arriving at "safety" recommendations that are excessively and inappropriately restrictive. While the directive to evaluate only the risks, and to ignore the benefits, of nutritional supplements created a rigged game, the members of the EVM appeared to be willing participants in that game.

If the EVM report is used to relegate currently available nutritional supplements to prescription-only status, then millions of people would be harmed, and very few would benefit. It would be of little consolation that the higher doses of vitamins and minerals could still be obtained with a doctor's prescription, because most doctors know less about nutrition than many of their patients do. Moreover, the overburdened health-care system is in no position to take on the job of gatekeeper of the vitamin cabinet; nor is there any need for it to do so.

Ironically, as flawed as the EVM report is, its recommendations may ultimately prove to be "as good as it gets" in Europe. Other European countries are recommending that maximum permitted levels be directly linked to multiples of the RDA, which could result in limits for some nutrients being set substantially lower than those suggested in the EVM report.

While some nutritional supplements can cause adverse effects in certain clinical situations or at certain doses, appropriate warning labels on vitamin and mineral products would provide ample protection against most of those risks.

FDA Legal Defense is Indefensible

Corruption Bought By Pharma Money

by Will Clower, Ph.D.

Janssen Pharmaceutica Products never hid damaging results, they "minimized potentially fatal safety risks and made misleading claims about the drug," according to a recent report in the New York Times. The product in question, Risperdal, is given to more than 10 million people worldwide. It was not until a doctor asserted that children could be hurt or killed by these drugs that the FDA obtained this admission by the company.

First there was the lawsuit. Then the drug company came clean about the side effects.

Zoloft - prescribed for depression - can produce suicidal thoughts in children, but this incredible oversight was not revealed when the FDA approved the drug. These are not isolated cases, according a 2002 study in the Journal of American Medical Association. There have been seven drug recalls after reports of death and severe health complications in the last 10 years. The complete list of food and drug recalls and alerts, month by exhaustive month, may be found at http://www.fda.gov/opacom/7alerts.html.

This constant stream does not reflect poorly on the FDA, which can only make decisions based on the quality of information they receive. The drug applications come from companies with a vested interest in convincing the FDA to approve. Corners often get cut, and the data get selected to optimize chances of acceptance. Hence, the recalls.

At present, the current Administration is arguing in court that FDA decisions should be immune to legal challenge. The argument basically states that, if the FDA approved it, you cannot sue the drug maker for any ill effects it causes you.

This curious deference to a governmental agency gives the FDA an ultimate say so, over which the individual has no recourse.

The Administration, however, argues that preventing litigation in these cases is good medicine. Freeing multi-billion dollar companies from the threat of lawsuits, it is contended, will provide a permissive environment for them. Otherwise, they might be too timid to develop a potentially lifesaving drug.

Even a quick glance at the FDA list of new drug trials argues against this possibility. To date, hundreds of new drug trials have been applied for, despite the present legal environment.

The irony is that the new authority given to the FDA does not benefit them in anyway. They make decisions based on data received in applications, and would never know if a drug company picked the best 1% of the data to submit, and neglected to reveal the rest. It is a common error to assume that the FDA performs the research themselves. It does not, but only evaluates the "best case" proposals it receives from pharmaceutical companies who desperately want their drugs approved.

Legally asserting that the FDA's decisions are final gives unprecedented protection for the drug companies. Once any drug is accepted by the agency, the company would be completely immune to liability.

In the meantime, anyone who suffered from an undisclosed side effect of a drug would have nowhere to turn. The law would shield the company, there's no one to vote out of office, and no one to contact (does anyone know the Board of Directors for Pfizer? Would you write them a letter?). Basic rights in this case would be forfeit.

Although this position is being actively pursued by the Administration, it's unclear that it would ever pass Constitutional muster. In fact, Duke University law scholar Erwin Chemerinsky remarked that "The Supreme Court has expressly ruled that FDA regulations do not preempt state law and local regulation."

We cannot speculate on the motivations of the Administration in becoming the champion for this Constitutionally questionable legal stance that empowers corporations at the expense of consumers. But we can say that it would produce a situation in which individuals would lose their most basic protections.

Will Clower is a Pittsburgh-based health writer, television host, and founder of The PATH Curriculum, The PATH Online, and Newsletter. The PATH: America's weight solution. Dr. Clower can be reached on his website www.fatfallacy.com.

Glaxo chief: Our drugs do not work on most patients

By Steve Connor, Science Editor, 08 December 2003

A senior executive with Britain's biggest drugs company has admitted that most prescription medicines do not work on most people who take them.

Allen Roses, worldwide vice-president of genetics at GlaxoSmithKline (GSK), said fewer than half of the patients prescribed some of the most expensive drugs actually derived any benefit from them.

It is an open secret within the drugs industry that most of its products are ineffective in most patients but this is the first time that such a senior drugs boss has gone public. His comments come days after it emerged that the NHS drugs bill has soared by nearly 50 per cent in three years, rising by £2.3bn a year to an annual cost to the taxpayer of £7.2bn. GSK announced last week that it had 20 or more new drugs under development that could each earn the company up to $1bn (£600m) a year.

Dr Roses, an academic geneticist from Duke University in North Carolina, spoke at a recent scientific meeting in London where he cited figures on how well different classes of drugs work in real patients.

Drugs for Alzheimer's disease work in fewer than one in three patients, whereas those for cancer are only effective in a quarter of patients. Drugs for migraines, for osteoporosis, and arthritis work in about half the patients, Dr Roses said. Most drugs work in fewer than one in two patients mainly because the recipients carry genes that interfere in some way with the medicine, he said.

"The vast majority of drugs - more than 90 per cent - only work in 30 or 50 per cent of the people," Dr Roses said. "I wouldn't say that most drugs don't work. I would say that most drugs work in 30 to 50 per cent of people. Drugs out there on the market work, but they don't work in everybody."

Some industry analysts said Dr Roses's comments were reminiscent of the 1991 gaffe by Gerald Ratner, the jewellery boss, who famously said that his high street shops are successful because they sold "total crap". But others believe Dr Roses deserves credit for being honest about a little-publicised fact known to the drugs industry for many years.

"Roses is a smart guy and what he is saying will surprise the public but not his colleagues," said one industry scientist. "He is a pioneer of a new culture within the drugs business based on using genes to test for who can benefit from a particular drug."

Dr Roses has a formidable reputation in the field of "pharmacogenomics" - the application of human genetics to drug development - and his comments can be seen as an attempt to make the industry realise that its future rests on being able to target drugs to a smaller number of patients with specific genes.

The idea is to identify "responders" - people who benefit from the drug - with a simple and cheap genetic test that can be used to eliminate those non-responders who might benefit from another drug.

This goes against a marketing culture within the industry that has relied on selling as many drugs as possible to the widest number of patients - a culture that has made GSK one of the most profitable pharmaceutical companies, but which has also meant that most of its drugs are at best useless, and even possibly dangerous, for many patients.

Dr Roses said doctors treating patients routinely applied the trial-and-error approach which says that if one drug does not work there is always another one. "I think everybody has it in their experience that multiple drugs have been used for their headache or multiple drugs have been used for their backache or whatever.

"It's in their experience, but they don't quite understand why. The reason why is because they have different susceptibilities to the effect of that drug and that's genetic," he said.

"Neither those who pay for medical care nor patients want drugs to be prescribed that do not benefit the recipient. Pharmacogenetics has the promise of removing much of the uncertainty."

Response rates

Therapeutic area: drug efficacy rate in per cent